International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons, International Journal of Cancer, vol.18, issue.1, pp.229-234, 2009. ,
DOI : 10.1002/ijc.24320
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048853
Epidemiology of primary bone tumors and economial aspects of bone metastases, Bone cancer, pp.5-9, 2015. ,
Low-grade central osteosarcoma In: IARC, editor. WHO classification of tumours of soft tissue and bone, pp.281-282, 2013. ,
editor. WHO classification of tumours of soft tissue and bone, pp.282-288, 2013. ,
Telangiectatic osteosarcoma In: IARC, editor. WHO classification of tumours of soft tissue and bone, pp.289-290, 2013. ,
Small cell osteosarcoma In: IARC, editor. WHO classification of tumours of soft tissue and bone, p.291, 2013. ,
In: IARC, editor. WHO classification of tumours of soft tissue and bone, pp.92-293, 2013. ,
Periosteal osteosarcoma In: IARC, editor. WHO classification of tumours of soft tissue and bone, p.294, 2013. ,
High-grade surface osteosarcoma In: IARC, editor. WHO classification of tumours of soft tissue and bone, pp.295-296, 2013. ,
Bone sarcomas: pathogenesis and new therapeutic approaches, IBMS BoneKEy, vol.17, issue.9, pp.402-414, 2011. ,
DOI : 10.1138/20110531
Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad, STEM CELLS, vol.70, issue.3, pp.397-403, 2011. ,
DOI : 10.1002/stem.596
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?, Bone, vol.62, pp.56-63, 2014. ,
DOI : 10.1016/j.bone.2014.02.003
Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations, Annals of Oncology, vol.27, issue.4, pp.738-744, 2016. ,
DOI : 10.1093/annonc/mdw009
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency, Nature Communications, vol.104, p.8940, 2015. ,
DOI : 10.1038/ncomms9940
Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease, Genes & Development, vol.22, issue.12, pp.1662-1676, 2008. ,
DOI : 10.1101/gad.1656808
Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice, Carcinogenesis, vol.30, issue.10, pp.1789-1795, 2009. ,
DOI : 10.1093/carcin/bgp180
Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage, Proceedings of the National Academy of Sciences, vol.105, issue.33, pp.11851-11856, 2008. ,
DOI : 10.1073/pnas.0805462105
Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA, Bone, vol.55, issue.1, pp.166-178, 2013. ,
DOI : 10.1016/j.bone.2013.02.016
OPG: new therapeutic targets in bone tumours and associated osteolysis, Biochim Biophys Acta, vol.1704, pp.49-57, 2004. ,
DOI : 10.1016/j.bbcan.2004.05.002
URL : https://hal.archives-ouvertes.fr/inserm-00669006
Cancer Stem Cell Niche: The Place to Be, Cancer Research, vol.71, issue.3, pp.634-639, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-3220
URL : http://hdl.handle.net/11245/1.385902
Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence, PLoS ONE, vol.17, issue.6, p.10999, 2010. ,
DOI : 10.1371/journal.pone.0010999.s001
URL : https://hal.archives-ouvertes.fr/inserm-00667931
Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells, Plastic and Reconstructive Surgery, vol.137, issue.3, pp.865-875, 2016. ,
DOI : 10.1097/01.prs.0000479989.88114.8b
A review of clinical and molecular prognostic factors in osteosarcoma, Journal of Cancer Research and Clinical Oncology, vol.25, issue.1, pp.281-297, 2008. ,
DOI : 10.1007/s00432-007-0330-x
A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era, Sarcoma, vol.12, issue.2, p.704872, 2012. ,
DOI : 10.1016/j.ejca.2011.05.030
Osteosarcoma incidence and survival rates from 1973 to 2004, Cancer, vol.19, issue.112, pp.1531-1543, 2009. ,
DOI : 10.1002/cncr.24121
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813207
The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma, Cancer, vol.15, issue.S3, pp.936-945, 1975. ,
DOI : 10.1002/1097-0142(197503)35:3+<936::AID-CNCR2820350714>3.0.CO;2-B
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity, New England Journal of Medicine, vol.314, issue.25, pp.1600-1606, 1986. ,
DOI : 10.1056/NEJM198606193142502
Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy, European Journal of Cancer, vol.41, issue.18, pp.2836-2845, 2005. ,
DOI : 10.1016/j.ejca.2005.08.026
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials, Annals of Oncology, vol.23, issue.6, pp.1607-1616, 2012. ,
DOI : 10.1093/annonc/mdr491
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360547
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup, European Journal of Cancer, vol.48, issue.5, pp.703-712, 2012. ,
DOI : 10.1016/j.ejca.2011.09.012
Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651, Journal of Clinical Oncology, vol.21, issue.8, pp.1574-1580, 2003. ,
DOI : 10.1200/JCO.2003.08.165
Current strategies of chemotherapy in osteosarcoma, International Orthopaedics, vol.42, issue.3, pp.445-451, 2006. ,
DOI : 10.1007/s00264-006-0192-x
Bone tumors: diagnosis, treatment and prognosis Philadelphia: WB Saunders, pp.85-156, 1991. ,
Margins and bone tumors ??? what are we talking about?, Bone cancer, pp.287-291, 2015. ,
DOI : 10.1016/B978-0-12-416721-6.00025-X
Do Surgical Margins Affect Local Recurrence and Survival in Extremity, Nonmetastatic, High-grade Osteosarcoma?, Clinical Orthopaedics and Related Research??, vol.36, issue.3, pp.677-683, 2016. ,
DOI : 10.1007/s11999-015-4359-x
Controversies in childhood osteosarcoma, Minerva Pediatr, vol.65, pp.125-148, 2013. ,
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment, Annals of Oncology, vol.26, issue.2, pp.407-414, 2015. ,
DOI : 10.1093/annonc/mdu526
MAPIE vs MAP as postoperative chemotherapy in patients with a poor response to preoperative chemotherapy for newly-diagnosed osteosarcoma: results from EURAMOS-1, Connective Tissue Oncology Society (CTOS), 2014. ,
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial, Journal of Clinical Oncology, vol.33, issue.20, pp.2279-2287, 2015. ,
DOI : 10.1200/JCO.2014.60.0734
The Role of Radiotherapy in Oseosarcoma, Cancer Treat Res, vol.152, pp.147-164, 2009. ,
DOI : 10.1007/978-1-4419-0284-9_7
Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group, Journal of Clinical Oncology, vol.21, issue.2, pp.334-341, 2003. ,
DOI : 10.1200/JCO.2003.01.142
Radiotherapy for local control of osteosarcoma, International Journal of Radiation Oncology*Biology*Physics, vol.61, issue.2, pp.492-498, 2005. ,
DOI : 10.1016/j.ijrobp.2004.05.051
Palliative therapy for osteosarcoma, Expert Review of Anticancer Therapy, vol.11, issue.2, pp.217-227, 2011. ,
DOI : 10.1586/era.10.172
Clinical outcomes of palliative radiation therapy for children, Practical Radiation Oncology, vol.5, issue.3, pp.183-187, 2015. ,
DOI : 10.1016/j.prro.2014.08.015
Targeted therapies for bone sarcomas, BoneKEy Reports, vol.2, p.378, 2013. ,
DOI : 10.1038/bonekey.2013.112
Current Therapeutic Strategies and Novel Approaches in Osteosarcoma, Cancers, vol.5, issue.2, pp.591-616, 2013. ,
DOI : 10.3390/cancers5020591
URL : http://doi.org/10.3390/cancers5020591
Advances in emerging drugs for osteosarcoma, Expert Opinion on Emerging Drugs, vol.133, issue.4, pp.495-514, 2015. ,
DOI : 10.1093/bioinformatics/btp618
Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma, Journal of Surgical Oncology, vol.56, issue.1, pp.21-27, 1998. ,
DOI : 10.1002/(SICI)1096-9098(199809)69:1<21::AID-JSO5>3.0.CO;2-M
Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray, Anticancer Res, vol.34, pp.3881-3889, 2014. ,
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial, The Lancet Oncology, vol.14, issue.4, pp.371-382, 2013. ,
DOI : 10.1016/S1470-2045(13)70049-4
Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors, Clinical Cancer Research, vol.17, issue.3, pp.611-619, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-1731
Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma, Cancer Research, vol.69, issue.6, pp.2443-2452, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-2645
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism, Oncogene, vol.274, issue.13, pp.1932-1940, 2006. ,
DOI : 10.1038/sj.onc.1209990
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC???S (Observatoire de l???Utilisation des Th??rapies Cibl??es dans les Sarcomes), BMC Cancer, vol.38, issue.Supplement 3, p.854, 2015. ,
DOI : 10.1186/s12885-015-1894-5
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers, Journal of Bone Oncology, vol.4, issue.1, pp.1-12, 2015. ,
DOI : 10.1016/j.jbo.2015.01.001
Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model, Journal of Clinical Oncology, vol.27, issue.19, pp.3148-3153, 2009. ,
DOI : 10.1200/JCO.2008.20.5054
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study, Pediatric Blood & Cancer, vol.111, issue.2, pp.254-258, 2008. ,
DOI : 10.1002/pbc.21132
Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium, Journal of Clinical Oncology, vol.29, issue.7, pp.839-844, 2011. ,
DOI : 10.1200/JCO.2010.30.7231
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program, Pediatric Blood & Cancer, vol.6, issue.1, pp.42-48, 2008. ,
DOI : 10.1002/pbc.21535
Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study, Clinical Cancer Research, vol.17, issue.15, pp.5113-5122, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-0237
Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program, Pediatric Blood & Cancer, vol.29, issue.3, pp.586-588, 2012. ,
DOI : 10.1002/pbc.24016
Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients, Acta Oncologica, vol.2, issue.10, pp.1451-1454, 2014. ,
DOI : 10.1200/JCO.2006.07.3049
Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors, Clinical Cancer Research, vol.19, issue.1, pp.236-246, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-1897
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study, Annals of Oncology, vol.23, issue.2, pp.508-516, 2012. ,
DOI : 10.1093/annonc/mdr151
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial, The Lancet Oncology, vol.16, issue.1, pp.98-107, 2015. ,
DOI : 10.1016/S1470-2045(14)71136-2
A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.18, issue.9, pp.2658-2667, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-1900
Molecular cloning of a new transforming gene from a chemically transformed human cell line, Nature, vol.170, issue.5981, pp.29-33, 1984. ,
DOI : 10.1038/311029a0
Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors, Am J Pathol, vol.149, pp.1209-1219, 1996. ,
Met oncogene aberrant expression in canine osteosarcoma, Journal of Orthopaedic Research, vol.270, issue.2, pp.253-256, 2000. ,
DOI : 10.1002/jor.1100180213
Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: A clinicopathologic and immunohistochemical study, Human Pathology, vol.31, issue.6, pp.709-716, 2000. ,
DOI : 10.1053/hupa.2000.8230
The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model, Journal of Bone and Mineral Research, vol.22, issue.6, pp.1283-1294, 2011. ,
DOI : 10.1002/jbmr.336
Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K???Akt signaling, Archives of Biochemistry and Biophysics, vol.526, issue.1, pp.38-43, 2012. ,
DOI : 10.1016/j.abb.2012.07.003
Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-343, 2004. ,
DOI : 10.1016/j.molmed.2004.05.007
Therapeutic Approach of Primary Bone Tumours by Bisphosphonates, Current Pharmaceutical Design, vol.16, issue.27, pp.2981-2987, 2010. ,
DOI : 10.2174/138161210793563554
URL : https://hal.archives-ouvertes.fr/inserm-00511241
Zoledronic Acid Activates the DNA S-Phase Checkpoint and Induces Osteosarcoma Cell Death Characterized by Apoptosis-Inducing Factor and Endonuclease-G Translocation Independently of p53 and Retinoblastoma Status, Molecular Pharmacology, vol.71, issue.1 ,
DOI : 10.1124/mol.106.028837
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells, Cellular Immunology, vol.249, issue.2, pp.63-72, 2007. ,
DOI : 10.1016/j.cellimm.2007.11.005
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005. ,
DOI : 10.1016/j.bone.2005.02.020
Zoledronic acid inhibits osteosarcoma growth in an orthotopic model, Molecular Cancer Therapeutics, vol.6, issue.12, pp.3263-3270, 2007. ,
DOI : 10.1158/1535-7163.MCT-07-0546
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice, Cancer, vol.91, issue.11, pp.2522-2529, 2005. ,
DOI : 10.1002/cncr.21530
Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model, Cancer Letters, vol.274, issue.2, pp.271-278, 2009. ,
DOI : 10.1016/j.canlet.2008.09.026
Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells, Cancer Letters, vol.250, issue.2, pp.194-205, 2007. ,
DOI : 10.1016/j.canlet.2006.10.004
Pleiotropic effects of bisphosphonates on osteosarcoma, Bone, vol.63, pp.110-120, 2014. ,
DOI : 10.1016/j.bone.2014.03.005
Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases, Cancer Research, vol.70, issue.18, pp.7063-7072, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-4291
1413OZOLEDRONATE DOES NOT REDUCE THE RISK OF TREATMENT FAILURE IN OSTEOSARCOMA: RESULTS OF THE FRENCH MULTICENTRE OS2006 RANDOMISED TRIAL, Annals of Oncology, vol.25, issue.suppl_4, pp.494-510, 2014. ,
DOI : 10.1093/annonc/mdu354.2
Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells, Journal of Cellular and Molecular Medicine, vol.14, issue.3, pp.928-994, 2008. ,
DOI : 10.1111/j.1582-4934.2008.00141.x
URL : https://hal.archives-ouvertes.fr/inserm-00667523
Development of stemness in cancer cell lines resistant to the anticancer effects of zoledronic acid, Anticancer Res, vol.36, pp.625-631, 2016. ,
Induction of ???? T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo, Blood, vol.102, issue.6, pp.2310-2311, 2003. ,
DOI : 10.1182/blood-2003-05-1655
Sensitization of human osteosarcoma cells to V??9V??2 T-cell-mediated cytotoxicity by zoledronate, Journal of Orthopaedic Research, vol.171, issue.5, pp.824-830, 2012. ,
DOI : 10.1002/jor.21579
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine & Growth Factor Reviews, vol.15, issue.6, pp.457-475, 2004. ,
DOI : 10.1016/j.cytogfr.2004.06.004
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B, The Journal of Pathology, vol.186, issue.5, pp.555-562, 2007. ,
DOI : 10.1002/path.2140
Receptor activator of nuclear factor ??B expression is a prognostic factor in human osteosarcoma, Oncology Letters, vol.10, pp.1813-1815, 2015. ,
DOI : 10.3892/ol.2015.3489
Impact of RANK signalling on survival and chemotherapy response in osteosarcoma, Pathology, vol.46, issue.5, pp.411-415, 2014. ,
DOI : 10.1097/PAT.0000000000000116
RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma, Pediatric Blood & Cancer, vol.116, issue.5, pp.738-743, 2011. ,
DOI : 10.1002/pbc.22720
RANK and RANK ligand expression in primary human osteosarcoma, Journal of Bone Oncology, vol.4, issue.3, pp.59-68, 2014. ,
DOI : 10.1016/j.jbo.2015.06.002
URL : http://doi.org/10.1016/j.jbo.2015.06.002
Therapeutic efficacy of soluble receptor activator of nuclear factor-??B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma, Molecular Cancer Therapeutics, vol.7, issue.10, pp.3389-3398, 2008. ,
DOI : 10.1158/1535-7163.MCT-08-0497
URL : https://hal.archives-ouvertes.fr/inserm-00332021
Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma, Drug Design, Development and Therapy, vol.9, pp.969-976, 2015. ,
DOI : 10.2147/DDDT.S77116
RANKL blockade prevents and treats aggressive osteosarcomas, Science Translational Medicine, vol.7, issue.317, pp.317-197, 2015. ,
DOI : 10.1126/scitranslmed.aad0295
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL???RANK signalling, Nature, vol.468, issue.7335, pp.548-553, 2011. ,
DOI : 10.1038/nature09707
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166217
Monoclonal antibodies targeting RANKL in bone metastasis treatment, Monoclonal antibodies in oncology. Uckum: eBook Future Medicine Ltd, pp.42-53, 2012. ,
DOI : 10.2217/ebo.12.295
RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?, Oncology, vol.88, issue.4, pp.257-260, 2015. ,
DOI : 10.1159/000369975
Genetically Modified T-Cell Therapy for Osteosarcoma, Adv Exp Med Biol, vol.804, pp.323-340, 2014. ,
DOI : 10.1007/978-3-319-04843-7_18
Potential of human ???? T cells for immunotherapy of osteosarcoma, Molecular Biology Reports, vol.15, issue.1, pp.427-437, 2013. ,
DOI : 10.1007/s11033-012-2077-y
Natural Killer Cells for Osteosarcoma, Adv Exp Med Biol, vol.804, pp.341-353, 2014. ,
DOI : 10.1007/978-3-319-04843-7_19
The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1826, issue.2, pp.434-442, 2012. ,
DOI : 10.1016/j.bbcan.2012.07.003
Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells, Cancer Biotherapy & Radiopharmaceuticals, vol.14, issue.2, pp.121-128, 1999. ,
DOI : 10.1089/cbr.1999.14.121
Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin, Clin Cancer Res, vol.1, pp.1595-1601, 1995. ,
Current Studies of Liposome Muramyl Tripeptide (CGP 19835A Lipid) Therapy for Metastasis in Spontaneous Tumors: A Progress Review*, Journal of Drug Targeting, vol.270, issue.5, pp.391-396, 1994. ,
DOI : 10.1111/j.1939-1676.1992.tb00339.x
Effect of Liposome-Muramyl Tripeptide Combined with Recombinant Canine Granulocyte Colony-Stimulating Factor on Canine Monocyte Activity, Cancer Biotherapy, vol.9, issue.2, pp.113-121, 1994. ,
DOI : 10.1089/cbr.1994.9.113
Cytostatic Activity of Canine Plastic-Adherent Mononuclear Cells Against Canine Osteosarcoma Cells, Cancer Biotherapy, vol.8, issue.2, pp.137-144, 1993. ,
DOI : 10.1089/cbr.1993.8.137
Therapy for Osteosarcoma in Dogs With Intravenous Injection of Liposome-Encapsulated Muramyl Tripeptide, JNCI Journal of the National Cancer Institute, vol.81, issue.12, pp.935-938, 1989. ,
DOI : 10.1093/jnci/81.12.935
An Immunologic Approach to the Treatment of Cancer, Veterinary Clinics of North America, vol.7, issue.1, pp.65-75, 1977. ,
DOI : 10.1016/S0091-0279(77)50006-8
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases, Expert Review of Anticancer Therapy, vol.8, issue.2, pp.151-159, 2008. ,
DOI : 10.1586/14737140.8.2.151
Mifamurtide for the treatment of nonmetastatic osteosarcoma, Expert Opinion on Pharmacotherapy, vol.50, issue.1, pp.285-292, 2011. ,
DOI : 10.1007/BF01741788
URL : https://hal.archives-ouvertes.fr/inserm-00667530
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival???A Report From the Children's Oncology Group, Journal of Clinical Oncology, vol.26, issue.4, pp.633-638, 2008. ,
DOI : 10.1200/JCO.2008.14.0095
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate, Journal of Clinical Oncology, vol.23, issue.9, pp.2004-2011, 2005. ,
DOI : 10.1200/JCO.2005.06.031
Review of mifamurtide in the treatment of patients with osteosarcoma, Therapeutics and Clinical Risk Management, vol.6, pp.279-286, 2010. ,
DOI : 10.2147/TCRM.S5688
Tumour-associated macrophages and cancer, Current Opinion in Pharmacology, vol.13, issue.4, pp.595-601, 2013. ,
DOI : 10.1016/j.coph.2013.05.017
Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid), Cancer Immunology Immunotherapy, vol.66, issue.A ,
DOI : 10.1007/BF01741788
Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma, American Journal of Clinical Oncology, vol.18, issue.2, pp.93-99, 1995. ,
DOI : 10.1097/00000421-199504000-00001
Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents, Clinical Cancer Research, vol.17, issue.8, pp.2110-2119, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-2047
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment, International Journal of Cancer, vol.1, issue.Suppl3 ,
DOI : 10.1002/ijc.29376
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma, Cancer, vol.39, issue.22, pp.5339-5348, 2009. ,
DOI : 10.1002/cncr.24566
Mechanisms of drug resistance in kinases, Expert Opinion on Investigational Drugs, vol.7, issue.4, pp.153-208, 2011. ,
DOI : 10.1016/j.bmcl.2007.01.048
May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol, International Journal of Oncology, vol.29, pp.1459-1468, 2006. ,
DOI : 10.3892/ijo.29.6.1459
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-??, Journal of Experimental & Clinical Cancer Research, vol.33, issue.1, p.27, 2014. ,
DOI : 10.1126/science.1198443
Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma, Cancer Res, vol.47, pp.5377-5381, 1987. ,
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma., Journal of Clinical Oncology, vol.16, issue.6, pp.2169-2180, 1998. ,
DOI : 10.1200/JCO.1998.16.6.2169
Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3, Cancer Science, vol.378, issue.Suppl 1, pp.1656-1664, 2012. ,
DOI : 10.1111/j.1349-7006.2012.02344.x
Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma, Clinical Sarcoma Research, vol.5, issue.1, p.4, 2015. ,
DOI : 10.1073/pnas.1302825110
Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma, Cancer, vol.4, issue.4, pp.548-554, 2014. ,
DOI : 10.1002/cncr.28461
Endothelin A Receptor Antagonism Enhances Inhibitory Effects of Anti-Ganglioside GD2 Monoclonal Antibody on Invasiveness and Viability of Human Osteosarcoma Cells, PLoS ONE, vol.142, issue.4, p.93576, 2014. ,
DOI : 10.1371/journal.pone.0093576.g008
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues, International Journal of Clinical Oncology, vol.331, issue.3, pp.456-461, 2016. ,
DOI : 10.1007/s10147-016-0959-z
Programmed Cell Death Ligand 1 Expression in Osteosarcoma, Cancer Immunology Research, vol.2, issue.7, pp.690-698, 2014. ,
DOI : 10.1158/2326-6066.CIR-13-0224
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082476
Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines, Pediatric Research, vol.46, issue.3, pp.371-377, 2016. ,
DOI : 10.1097/CJI.0b013e31821ca6ce
The future of immunotherapy for sarcoma, Expert Opinion on Biological Therapy, vol.137, issue.9, pp.1-9, 2016. ,
DOI : 10.1038/nrc3322
Dual Faces of IFN?? in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity, Clinical Cancer Research, vol.22, issue.10, pp.2329-2334, 2016. ,
DOI : 10.1158/1078-0432.CCR-16-0224
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?, Drugs, vol.2, issue.Suppl 3, pp.925-945, 2016. ,
DOI : 10.1111/pcmr.12340
Antitumor dendritic cell???based vaccines: lessons from 20??years of clinical trials and future perspectives, Translational Research, vol.168, pp.74-95, 2016. ,
DOI : 10.1016/j.trsl.2015.07.008
Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats, Cancer Research, vol.68, issue.22, pp.9433-9440109, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-0104
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma, Cancer Immunology, Immunotherapy, vol.18, issue.23, pp.1251-1260, 2015. ,
DOI : 10.1007/s00262-015-1731-3
Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma, Clinical and Translational Oncology, vol.39, issue.4, pp.271-279, 2012. ,
DOI : 10.1007/s12094-012-0795-1
Systemic Targeted Alpha Radiotherapy for Cancer - A Review, Bangladesh Journal of Medical Physics, vol.6, issue.1, pp.67-80, 2013. ,
DOI : 10.3329/bjmp.v6i1.19755
Bone-Seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223, Adv Exp Med Biol, vol.804, pp.291-304, 2014. ,
DOI : 10.1007/978-3-319-04843-7_16
Targeting of osseous sites with alpha-emitting 223 Ra: comparison with the beta-emitter 89 Sr in mice, J Nucl Med, vol.44, pp.252-259, 2003. ,
First Clinical Experience with ??-Emitting Radium-223 in the Treatment of Skeletal Metastases, Clinical Cancer Research, vol.11, issue.12, pp.4451-4459, 2005. ,
DOI : 10.1158/1078-0432.CCR-04-2244
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial, The Lancet Oncology, vol.15, issue.7, pp.738-746, 2014. ,
DOI : 10.1016/S1470-2045(14)70183-4
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115, Journal of Medicinal Chemistry, vol.58, issue.14, pp.5599-5608, 2015. ,
DOI : 10.1021/acs.jmedchem.5b00627
Beyond DNA Repair: DNA-PK Function in Cancer, Cancer Discovery, vol.4, issue.10, pp.1126-1139, 2014. ,
DOI : 10.1158/2159-8290.CD-14-0358
459 Preclinical characterization of CC-115, a novel inhibitor of DNA-PK and mTOR kinase currently under clinical investigation, European Journal of Cancer, vol.50, issue.6, p.50, 2014. ,
DOI : 10.1016/S0959-8049(14)70585-4
Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63, Tumor Biology, vol.19, issue.12, pp.9365-9372, 2015. ,
DOI : 10.1007/s13277-015-3642-5
Targeting CDK4 and CDK6: From Discovery to Therapy, Cancer Discovery, vol.6, issue.4, pp.353-367, 2016. ,
DOI : 10.1158/2159-8290.CD-15-0894
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821753
Gpnmb/osteoactivin, an attractive target in cancer immunotherapy, Neoplasma, vol.59, issue.01, pp.1-5, 2012. ,
DOI : 10.4149/neo_2012_001
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma, Pediatric Blood & Cancer, vol.33, issue.1, pp.32-38, 2016. ,
DOI : 10.1002/pbc.25688
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology, Advanced Drug Delivery Reviews, vol.66, pp.2-25, 2014. ,
DOI : 10.1016/j.addr.2013.11.009
Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma, Pediatric Blood & Cancer, vol.19, issue.11, pp.2096-2098, 2014. ,
DOI : 10.1002/pbc.25062
Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression, Clinical Cancer Research, vol.21, issue.5, pp.1139-1150, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-1882
Progress in Radiotherapy for Pediatric Sarcomas, Current Oncology Reports, vol.102, issue.4, pp.320-326, 2012. ,
DOI : 10.1007/s11912-012-0235-y
Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk, Cancer, vol.95, issue.18, pp.4555-4563, 2012. ,
DOI : 10.1002/cncr.27451
Carbon-ion radiotherapy of spinal osteosarcoma with long-term follow, European Spine Journal, vol.7, issue.Suppl 1, pp.113-117, 2016. ,
DOI : 10.1007/s00586-015-4202-9
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.22, issue.6, pp.1364-1370, 2016. ,
DOI : 10.1158/1078-0432.CCR-15-0491
Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice, Tumor Biology, vol.25, issue.7, pp.9535-9548, 2016. ,
DOI : 10.1007/s13277-016-4837-0
Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets, Cancer Letters, vol.370, issue.2, pp.268-274, 2016. ,
DOI : 10.1016/j.canlet.2015.11.003
Osteosarcoma Stem Cells Have Active Wnt/??-catenin and Overexpress SOX2 and KLF4, Journal of Cellular Physiology, vol.12, issue.4, pp.876-886, 2016. ,
DOI : 10.1002/jcp.25179
Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells, Cancer Research, vol.74, issue.6, pp.1645-150, 2014. ,
DOI : 10.1158/0008-5472.CAN-13-1739
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959622
Circulating tumor cells in sarcomas: a brief review, Medical Oncology, vol.7, issue.3, p.430, 2015. ,
DOI : 10.1007/s12032-014-0430-9
Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation, Clinical Chemistry, vol.62, issue.4, pp.571-581, 2016. ,
DOI : 10.1373/clinchem.2015.249706
URL : https://hal.archives-ouvertes.fr/inserm-01466107
Digital Sorting of Pure Cell Populations Enables Unambiguous Genetic Analysis of Heterogeneous Formalin-Fixed Paraffin-Embedded Tumors by Next Generation Sequencing, Scientific Reports, vol.27, issue.1, p.20944, 2016. ,
DOI : 10.1093/bioinformatics/btq635